Cyclophosphamide in treatment of systemic lupus erythematosus: 7 years' experience.
This paper describes our experience with cyclophosphamide in the treatment of systemic lupus erythematosus. Since 1965 42 such patients have been treated either singly with cyclophosphamide or in combination with steroid. Serious complications have been rare except for amenorrhoea, which occurred in 14 out of 32 patients within the reproductive period. Our experience suggests that cyclophosphamide has an important, though not primary, part to play in the therapy of this disease.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001772:Blood Cell Count; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006417:Hematuria / Q000209:etiology; D006801:Humans; D007275:Injections, Intravenous; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D014508:Urea / Q000097:blood
D003520:Cyclophosphamide; D014508:Urea; D011239:Prednisolone